trending Market Intelligence /marketintelligence/en/news-insights/trending/bo0ykNLbo66y6xHvcxHmSA2 content esgSubNav
In This List

Celgene closes additional $30M investment in billionaire Soon-Shiong's company

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Celgene closes additional $30M investment in billionaire Soon-Shiong's company

Celgene Corp. further invested $30 million in privately held immunotherapy company NantCell Inc. bringing its total investment to $105 million.

Celgene, which is being acquired by Bristol-Myers in a $74 billion deal, now holds a 2.8% ownership in Los Angeles-based NantCell following completion of the financing.

The Summit, N.J.-based maker of blood cancer drug Revlimid first made a $75 million investment in NantCell in May 2015.

NantCell, headed and founded by billionaire Patrick Soon-Shiong, is developing a cancer vaccine to fight multiple tumor types without high-dose chemotherapy. The company owns a portfolio of biological molecules, with 27 in preclinical development while 14 in various phases of clinical development.